Home›Stock Screener›Jenburkt Pharmaceuticals›Financial Statements

Jenburkt Pharmaceuticals Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Jenburkt Pharmaceuticals (JENBURPH) reported revenue ₹169 Cr, net profit ₹34 Cr and EPS ₹78.71, with a net profit margin of 20.1% and ROE of 19.8%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore JENBURPH investment value to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 20.12% 2026 data
EBITDA Margin 23.67% 2026 data
Operating Margin 24.00% 2026 data
Return on Assets 17.35% 2026 data
Return on Equity 19.77% 2026 data

Balance Sheet Ratios

Current Ratio 9.50 2026 data
Equity Ratio 87.76% 2026 data
Asset Turnover 0.86 2026 data

JENBURPH Revenue, Net Profit & EBITDA — Year-on-Year Growth

JENBURPH YoY (March 2025 vs March 2026) — revenue +7.0%, net profit +6.3%, EBITDA -14.9%, expenses +16.2%. For live price, earnings ratios and company overview, see JENBURPH screener.

Revenue Growth
+7.0%
Year-over-Year
Net Profit Growth
+6.3%
Year-over-Year
EBITDA Growth
-14.9%
Year-over-Year
Expense Growth
+16.2%
Year-over-Year
Assets Growth
+18.8%
Year-over-Year
Equity Growth
+18.6%
Year-over-Year
Operating Cash Flow Growth
+250.0%
Year-over-Year
Investing Cash Flow Growth
-1600.0%
Year-over-Year
Financing Cash Flow Growth
-14.3%
Year-over-Year

JENBURPH Income Statement — Revenue, EBITDA & Net Profit

Jenburkt Pharmaceuticals revenue ₹169 Cr, EBITDA ₹40 Cr, net profit ₹34 Cr, EPS ₹78.71 (2026) — net profit margin 20.1%. Review JENBURPH PE ratio trends to evaluate earnings-based valuation against sector peers.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 169 158 147 142 129 114 123 126 118 106 96 87
Expenses 129 111 109 106 97 90 99 98 91 84 77 70
EBITDA 40 47 38 36 32 24 24 28 27 23 19 17
Operating Profit Margin % 24.00% 27.00% 23.00% 22.00% 22.00% 18.00% 17.00% 20.00% 21.00% 19.00% 18.00% 18.00%
Depreciation 3 3 2 2 2 2 2 1 2 2 2 3
Interest 0 1 0 0 0 1 1 0 0 0 0 0
Profit Before Tax 47 44 35 33 30 22 21 27 25 21 17 14
Tax 13 12 9 8 8 5 6 7 8 7 6 5
Net Profit 34 32 26 25 22 17 15 20 17 14 11 10
Earnings Per Share (₹) 78.71 72.65 58.86 53.90 48.58 35.96 32.40 43.14 37.50 29.05 23.18 20.75

JENBURPH Balance Sheet — Assets, Liabilities & Shareholders' Equity

JENBURPH total assets ₹196 Cr, total equity ₹172 Cr, total liabilities ₹ Cr (2025) — ROE 19.8%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 196 165 142 143 121 104 103 78 76 58 61
Current Assets 57 110 81 76 80 90 90 66 64 45 49
Fixed Assets 15 10 10 11 11 12 10 10 11 12 12
Capital Work in Progress 40 1 1 0 0 0 1 0 0 0 0
Investments 21 17 11 8 7 4 5 5 2 0 0
Other Assets 121 137 119 123 104 88 87 63 64 46 49
LIABILITIES
Total Liabilities
Current Liabilities 6 4 4 4 5 5 3 3 4 4 4
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 172 145 122 117 99 80 78 61 54 40 33
Share Capital 4 4 4 5 5 5 5 5 5 5 5
Reserves & Surplus 167 141 118 113 94 75 73 57 50 36 29

JENBURPH Cash Flow Statement — Operating, Investing & Financing

Jenburkt Pharmaceuticals operating cash flow ₹28 Cr, investing ₹-17 Cr, financing ₹-8 Cr, net cash flow ₹3 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 28 8 17 9 20 15 13 16 10 8 9
Investing Activities -17 -1 3 -1 -19 -3 -11 1 -10 0 1
Financing Activities -8 -7 -21 -6 -1 -11 -2 -18 1 -5 1
Net Cash Flow 3 1 -1 3 0 1 0 -1 1 2 11